Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Pulsed UVA CXL for Keratoconus
NCT05027295Phase 3Unknown
- Sponsor
- Cornea and Laser Eye Institute
- Start
- Jul 2021
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of riboflavin in keratoconus, corneal ectasia, sponsored by Cornea and Laser Eye Institute. Status: unknown.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT05027295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027295.